...We Welcome You To The Resverlogix HUB On AGORACOM!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: Now is the time over late spring and summer

Rocketman,

I doubt that there will be a cone of silence for too much longer. As I posted yesterday, the SSRA/FA at 75% of events is a huge inflection point. Assuming that the interim analysis is positive (best case scenario trial continues with no changes), then I expect management to shout from the hilltops. I agree, it would be great to have a conference call with Q&A. BIO International coming up in exactly 3 weeks is an opportunity. But probably not too much to be said if the SSRA still hasn't been triggered by then. 

BearDownAZ

Share
New Message
Please login to post a reply